Tag Archives: Multiple Myeloma

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

March 5, 2017

0 Comments

Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez, Kyle Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R Berenson Haematologica December 2016 : haematol.2016.150896; doi:10.3324/haematol.2016.150896 Abstract B-cell maturation antigen is expressed on plasma cells. In this study, we have […]

Continue reading...

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib

March 5, 2017

0 Comments

  Ariana Berenson Suzie Vardanyan Michael David James Wang Nika Manik Harutyunyan Jillian Gottlieb Ran Halleluyan Tanya M. Spektor Kyle A. Udd Shahrooz Eshaghian Youram Nassir Benjamin Eades Regina Swift James R. Berenson Abstract New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma (MM) patients during the past decade. However, most of the studies reporting outcomes […]

Continue reading...

What’s New in Myeloma?

June 27, 2013

0 Comments

There have been several recent breakthroughs for the treatment of multiple myeloma patients that have led to new therapeutic options. With regards to newer agents, there are a number of new drugs in development.  The most promising are the antibody-based treatments for myeloma involving proteins on the outside of myeloma cells that are called CD38, […]

Continue reading...

Understanding Myeloma News About Secondary Cancers and Clotting

May 28, 2012

0 Comments

Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.

Continue reading...